B+
Bull case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NXTC
NextCureDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Avere transaction and associated financing could provide a new capital base, while CVRs and LigaChem's continued LNCB74 development preserve potential legacy-asset optionality. [#SEC-8K-2026-08-06]
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -6.2.
What can break
Continued cash burn, restructuring costs, and potential dilution or financing risk.
Momentum
98
Value
41
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $9.50 · Bear $2.40Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $20.00
Why
Momentum98 · Δ7d -0.4
Value41 · Δ7d -0.0
Sentiment33 · Δ7d -6.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -6.2.
Contradictions & invalidation
- • Continued cash burn, restructuring costs, and potential dilution or financing risk.
- • LNCB74 milestone and royalty potential is contingent and lacks quantified timing or economics.
- • The merger remains conditional, NextCure is in clinical transition, cash is declining, and SIM0505 development visibility has weakened after the previously disclosed U.S.
Catalyst clock
2026-08-31
Q2 cash decline and restructuring pressure
Lead driver: Sentiment · See AI snapshot
Momentum
98
9% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-0.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
33
62% active weight
Current posture
7d trendSoftening
Δ7d
-6.2
Δ21d
-16.1
Why this grade
Composite grade D. Momentum 98.2 / Value 41.2 / Sentiment 33.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$35.29M
Beta
1.55
Shares Out
4.58M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.87
Rev YoY
-100.0%
EPS YoY
-75.2%
Gross Margin
-
Op Margin
-
Net Debt
-$36.67M
Current Ratio
3.47
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data